This is a summary of the European public assessment report (EPAR) for Rapilysin. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Rapilysin.
Therapeutic Indication
### Therapeutic indication Rapilysin is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left bundle branch block within 12 hours after the onset of acute-myocardial-infarction (AMI) symptoms.
Therapeutic Area (MeSH)
ATC Code
B01AD07
ATC Item
reteplase
Pharmacotherapeutic Group
Antithrombotic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| reteplase | N/A | 瑞替普酶 |
EMA Name
Rapilysin
Medicine Name
Rapilysin
Aliases
N/ANo risk management plan link.
